

Early and locally advanced breast cancer: diagnosis and management - Neoadjuvant chemotherapy and ovarian function suppression (update)

Date: 27/09/2024

Location: Virtual

Minutes: Final

Committee members present:

Adam Firth	Chair	Present for notes 1 - 10
Ramsey Cutress	Topic Adviser	Present From partway through item 7 - 10
Kwok Leung Cheung	Breast surgeon	Present for notes 1 - 10
Mark Davies	Medical oncologist	Present for notes 3 - 10
Kay Davies-Crowley	Nurse specialist	Present for notes 1 - 10
Rachael Griffin	Lay member	Present for notes 1 - 10
Elinor Sawyer	Clinical oncologist	Present for notes 1 - 10
David Talbot	Lay member	Present for notes 1 - 10
Ben Thwaites	Pharmacist	Present for notes 1 - 10

In attendance:

Sarah Boyce	Senior Technical Analyst	Present for notes 1 - 10
Victoria Carter	Implementation Support Manager	Present for notes 1 - 10
Lindsay Claxton	Health Economics Adviser	Present for notes 1 - 10
Gareth Haman	Senior Guidance Content Designer	Present for notes 1 - 10
Marie Harrisingh	Topic Lead	Present for notes 1 - 10
Yolanda Martinez	Technical Analyst	Present for notes 1 - 10
Adam O'Keefe	Project Manager	Present for notes 1 - 10
Katherine Saxby	Medicines Adviser	Present for notes 1 - 10
Hannah Tebbs	Senior Health Economist	Present for notes 1 - 10

Apologies:

Milly Finch	Pharmacist
Sadaf Haque	GP
Tim Robinson	Medical oncologist
Katy Tan	Lay member
Andrea Heath	Senior Information Specialist, NICE
Adam Storrow	Business Analyst, Resource Impact Assessment, NICE

1. Welcome, introductions and apologies

The Chair welcomed the committee members and NICE attendees to the third committee meeting for the Neoadjuvant chemotherapy and ovarian function suppression update to the NICE Early and locally advanced breast cancer: diagnosis and management guideline.

The Chair informed the Committee that apologies had been received. These are noted above.

2. Minutes of the last meeting

The Chair asked the group to ratify the minutes of the second meeting on 6 September which were circulated as part of the papers. All agreed that they were an accurate reflection of the meeting.

3. Declarations of interest

The Chair confirmed that, for the purpose of managing conflicts of interest, the matter under discussion was Neoadjuvant chemotherapy and ovarian function suppression.

The Chair asked everyone to verbally declare any new interests. The following new interests were declared:

Name	Declaration	Date DOI arose	Action
Mark Davies	Travel expense paid by Fields Institute in Toronto to attend workshop on mathematical oncology	Sep 2024	Declare and participate Rationale: Non-specific
Rachael Griffin	RG company Jazz Pharmaceuticals are in clinical trials developing a drug called Zanidatamab for HER2 positive cancers including breast. RG not working on this drug.	Sep 2024	Declare and participate Rationale: Indirect interest

The Chair and a senior member of the Developer's team noted that neither this interest nor any previously declared interests would prevent attendees from fully participating in

the meeting.

4. Continue End of guideline restructuring discussion' from previous meeting; Neoadjuvant SACT diagrams

The Chair introduced NICE Technical Adviser, Marie Harrisingh who discussed the structure of NICE Guideline NG101 with the committee, including whether sections of the guideline need reorganising.

MH then presented and sought the groups' input on draft visual summaries produced in support of the guideline. The committee agreed these were useful and advised how they could be improved, so the NICE team agreed to retain and update these following the meeting.

5-9. Review Question 2.1: What is the clinical and cost effectiveness of ovarian function suppression combined with endocrine therapy using tamoxifen or aromatase inhibitors in people with oestrogen receptor positive invasive breast cancer that is local or locally advanced who have female reproductive organs and are premenopausal or perimenopausal?

The Chair introduced NICE Technical Analyst Yolanda Martinez who presented the clinical evidence identified for this review question. The Chair introduced NICE Senior Health Economist Hannah Tebbs who advised the committee that no Health economic evidence had been identified for this review question before discussing costs related to this treatment with the group. The committee discussed the evidence presented and any health inequalities considerations before drafting recommendations.

10. AOB, Summary and next steps

The Chair outlined next steps following the meeting, thanked the committee for their contributions, summarised the main actions from the day and asked for items of any other business. As there was no further business to discuss, the Chair brought the meeting to a close.

Date of next meeting: 08/11/2024

Location of next meeting: Virtual